Initiate antibacterial treatment early in patients with carbapenem-resistant or extensively drug-resistant Acinetobacter baumannii infection

被引：0

作者：

Adis Medical Writers ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Mairangi Bay, North Shore, Auckland

来源：

Drugs & Therapy Perspectives | 2015年 / 31卷 / 2期

关键词：

Colistin; Carbapenem; Antibacterial Therapy; Tigecycline; Fosfomycin;

D O I：

10.1007/s40267-014-0173-x

中图分类号：

学科分类号：

摘要：

Survival is consistently improved with early initiation of appropriate antibacterial therapy in patients with carbapenem-resistant or extensively drug-resistant Acinetobacter baumannii infections. However, because of a general lack of data, there is no clear consensus for the optimum empirical antibacterial therapy in these patients. Regimens that include colistin, sulbactam or tigecycline have been the most widely evaluated. © 2014, Springer International Publishing Switzerland.

引用

页码：57 / 61

页数：4

共 35 条

[1]

Viehman J.A., Nguyen M.H., Doi Y., Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections, Drugs, 74, 12, pp. 1315-1333, (2014)

[2]

Magiorakos A.P., Srinivasan A., Carey R.B., Et al., Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, 18, 3, pp. 268-281, (2012)

[3]

Woodford N., Turton J.F., Livermore D.M., Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance, FEMS Microbiol Rev, 35, 5, pp. 736-755, (2011)

[4]

Mera R.M., Miller L.A., Amrine-Madsen H., Et al., Acinetobacter baumannii 2002–2008: increase of carbapenem-associated multiclass resistance in the United States, Microb Drug Resist, 16, 3, pp. 209-215, (2010)

[5]

Chuang Y.C., Sheng W.H., Li S.Y., Et al., Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia, Clin Infect Dis, 52, 3, pp. 352-360, (2011)

[6]

Ng T.M., Teng C.B., Lye D.C., Et al., A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia, Infect Control Hosp Epidemiol, 35, 1, pp. 49-55, (2014)

[7]

Sheng W.H., Liao C.H., Lauderdale T.L., Et al., A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii, Int J Infect Dis, 14, 9, pp. 764-766, (2010)

[8]

Lemos E.V., de la Hoz F.P., Einarson T.R., Et al., Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis, Clin Microbiol Infect, 20, 5, pp. 416-423, (2014)

[9]

Lee H.Y., Chen C.L., Wu S.R., Et al., Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients, Crit Care Med, 42, 5, pp. 1081-1088, (2014)

[10]

Esterly J.S., Griffith M., Qi C., Et al., Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections, Antimicrob Agents Chemother, 55, 10, pp. 4844-4849, (2011)

← 1 2 3 4 →